CX Institutional lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 113.4% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 64,782 shares of the company’s stock after acquiring an additional 34,418 shares during the period. CX Institutional’s holdings in Johnson & Johnson were worth $17,150,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Silver Coast Investments LLC grew its position in Johnson & Johnson by 3.8% during the 2nd quarter. Silver Coast Investments LLC now owns 1,066 shares of the company’s stock worth $271,000 after purchasing an additional 39 shares during the last quarter. Townsend Asset Management Corp NC ADV lifted its stake in shares of Johnson & Johnson by 0.6% during the second quarter. Townsend Asset Management Corp NC ADV now owns 6,418 shares of the company’s stock worth $1,630,000 after buying an additional 39 shares during the period. Triumph Capital Management grew its holdings in shares of Johnson & Johnson by 1.6% during the second quarter. Triumph Capital Management now owns 2,531 shares of the company’s stock valued at $643,000 after buying an additional 39 shares during the last quarter. Denali Advisors LLC increased its position in shares of Johnson & Johnson by 1.2% in the 2nd quarter. Denali Advisors LLC now owns 3,305 shares of the company’s stock valued at $839,000 after acquiring an additional 40 shares during the period. Finally, Beaird Harris Wealth Management LLC increased its position in shares of Johnson & Johnson by 1.8% in the 4th quarter. Beaird Harris Wealth Management LLC now owns 2,422 shares of the company’s stock valued at $501,000 after acquiring an additional 42 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.
Johnson & Johnson Stock Performance
Johnson & Johnson stock traded down $2.72 during midday trading on Friday, hitting $255.94. 10,250,638 shares of the company were exchanged, compared to its average volume of 7,993,228. The business has a fifty day simple moving average of $266.52 and a two-hundred day simple moving average of $248.31. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09. The firm has a market capitalization of $616.79 billion, a PE ratio of 29.66, a price-to-earnings-growth ratio of 2.60 and a beta of 0.21. Johnson & Johnson has a fifty-two week low of $182.94 and a fifty-two week high of $281.07.
Johnson & Johnson Dividend Announcement
The company also recently declared a quarterly dividend, which was paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th were issued a dividend of $1.34 per share. The ex-dividend date of this dividend was Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a yield of 2.1%. Johnson & Johnson’s dividend payout ratio is 62.11%.
Analysts Set New Price Targets
Several analysts have weighed in on the company. Royal Bank Of Canada boosted their price target on Johnson & Johnson from $265.00 to $287.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Raymond James Financial set a $280.00 target price on Johnson & Johnson in a report on Monday, August 3rd. Morgan Stanley increased their price target on shares of Johnson & Johnson from $284.00 to $294.00 and gave the stock an “overweight” rating in a report on Thursday, July 16th. Argus set a $300.00 price target on shares of Johnson & Johnson in a research report on Wednesday, July 29th. Finally, Weiss Ratings raised shares of Johnson & Johnson from a “buy (b-)” rating to a “buy (b)” rating in a report on Friday, July 24th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $275.87.
Read Our Latest Research Report on Johnson & Johnson
Johnson & Johnson News Summary
Here are the key news stories impacting Johnson & Johnson this week:
- Positive Sentiment: ICOTYDE delivers durable psoriasis results: New Phase 3 ICONIC-TOTAL data showed sustained skin clearance through two years. At Week 112, 70% of patients achieved clear or almost clear skin, while complete clearance reached 89% for genital psoriasis and 60% for scalp psoriasis, with no new safety concerns reported. The results support ICOTYDE as a potential important first-line systemic treatment and strengthen J&J’s immunology pipeline. J&J ICOTYDE psoriasis data
- Positive Sentiment: Innovative Medicine growth remains a key offset: Analysts expect oncology products and newer launches to drive another quarter of growth, helping counter revenue erosion from Stelara biosimilars. This supports the investment case that J&J can replace lost exclusivity revenue with newer products. Innovative Medicine Q3 growth drivers
- Positive Sentiment: IMAAVY adds pipeline support: New data in generalized myasthenia gravis gives investors additional evidence that J&J’s immunology portfolio could provide future growth beyond current blockbuster medicines. IMAAVY data update
- Neutral Sentiment: J&J continues to receive favorable valuation commentary and analyst support after a strong one-year advance, but its approximately 30-times earnings valuation leaves less room for disappointment.
- Negative Sentiment: Stelara biosimilar pressure remains the central risk: The expected decline in Stelara sales is weighing on near-term growth comparisons and may be contributing to investor caution despite positive pipeline news.
Insider Activity
In other news, EVP Elizabeth Forminard sold 15,918 shares of the firm’s stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the sale, the executive vice president directly owned 16,994 shares in the company, valued at $4,367,458. This trade represents a 48.37% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Jennifer L. Taubert sold 15,000 shares of Johnson & Johnson stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the transaction, the executive vice president owned 194,451 shares of the company’s stock, valued at approximately $51,210,615.36. This represents a 7.16% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 87,569 shares of company stock worth $23,064,544 in the last ninety days. Corporate insiders own 0.16% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.
The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.
Featured Articles
- Five stocks we like better than Johnson & Johnson
- AST SpaceMobile’s BlueBird Progress Comes With Several Risks Still Unresolved
- Time to Nibble on MCD Stock After it Enters Oversold Territory?
- McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal Upside
- Corning and AT&T’s $3 Billion Fiber Deal Reveals Where AI Spending Goes Next
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
